Abstract:Background: Recent genomic profiling has identified a subtype of prostate cancer (PCa) characterized by two key genetic alterations: missense mutation of speckle-type POZ protein (SPOP) and homozygous deletion of chromodomain helicase DNA-binding protein 1 (CHD1). Mutually exclusive with E26 transformation-specific (ETS) rearrangements, this subtype displays high genomic instability. Previous studies indicate that deficient SPOP or CHD1 alone leads to feeble prostate abnormalities and each protein is involved in DNA damage response (DDR). It remains to be determined whether CHD1 and SPOP cooperate to suppress prostate tumorigenesis and DDR. Methods: Prostate-specific single or double knockout of Spop and Chd1 was generated with the Cre/loxP system in mice. Wild-type or mutant SPOP (F102C, F133V) overexpression and CHD1 knockdown with short hairpin RNA were created in human benign prostatic hyperplasia cell line BPH1. The levels of DNA damage and homologous recombination repair were measured by immunofluorescence staining of γH2AX and RAD51, respectively. Results: Spop/Chd1 double-knockout mice displayed prostatic intraepithelial neoplasia at both young (3 months) and old (12 months) ages and failed to generate prostate adenocarcinoma. Compared with wild-type or single-knockout mice, the double-knockout prostate harbored moderately higher proliferating cells and dramatically augmented the level of γH2AX staining, although androgen receptor-positive cells and apoptotic cells remained at a similar level. In BPH1 cell line, SPOP mutant overexpression and CHD1 silencing synergistically sensitized the cells to DNA damage by camptothecin, an inducer of double-strand breaks. Conclusions: Our results indicate that SPOP and CHD1 can synergistically promote repair of naturally occurring or chemically induced DNA damages in prostate epithelial cells. Regarding the progression of the SPOP/CHD1 subtype of PCa, other functionally complementary drivers warrant further identification. The clinical implication is that this subtype of PCa may be particularly sensitive to poly(ADP-ribose) polymerase inhibitors or DNA-damaging agents.

CHD6 promotes broad nucleosome eviction for transcriptional activation in prostate cancer cells

Chromatin Helicase CHD6 Establishes Pro-inflammatory Enhancers and is a Synthetic Lethal Target in FH-Deficient Renal Cell Carcinoma.

Human Homolog of Drosophila Hairy and Enhancer of Split 1, Hes1, Negatively Regulates Δ-Catenin (CTNND2) Expression in Cooperation with E2F1 in Prostate Cancer

Targeting XPO6 Inhibits Prostate Cancer Progression and Enhances the Suppressive Efficacy of Docetaxel

The chromatin remodeler CHD6 promotes colorectal cancer development by regulating TMEM65-mediated mitochondrial dynamics via EGF and Wnt signaling

Epigenetic identification of CHD5 as a critical 1p36.3 tumor suppressor frequently inactivated by promoter methylation in multiple carcinomas

Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer

ZNF143-Mediated H3K9 Trimethylation Upregulates CDC6 by Activating MDIG in Hepatocellular Carcinoma

CHD5 is down-regulated through promoter hypermethylation in gastric cancer

Molecular characteristics and oncogenic role of CHD family genes: a pan-cancer analysis based on bioinformatic and biological analysis

KDM6B is an androgen regulated gene and plays oncogenic roles by demethylating H3K27me3 at cyclin D1 promoter in prostate cancer

CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes

MYC reshapes CTCF-mediated chromatin architecture in prostate cancer

The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer

CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage

SIRT6 Promotes the Progression of Prostate Cancer via Regulating the Wnt/β-Catenin Signaling Pathway

CHD4 Promotes Breast Cancer Progression As a Coactivator of Hypoxia-Inducible Factors.

MYH6 suppresses tumor progression by downregulating KIT expression in human prostate cancer

CBX4 plays a bidirectional role in transcriptional regulation and lung adenocarcinoma progression

CHD1 Loss Sensitizes Prostate Cancer to DNA Damaging Therapy by Promoting Error-Prone Double-Strand Break Repair

Integrative Analysis Reveals the Transcriptional Collaboration Between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression